Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of ...

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

The current study shows that the Epstein–Barr virus can interfere with the normal control of B cells. One viral protein ...

Immunoglobulin G oligoclonal bands in CSF are highly prevalent in MS and CIS, with positive status associated with a significantly earlier age of disease onset.

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

A new study from Norway found a 42% lower risk of developing MS among women with greater dietary vitamin D intake, ...

Many women with multiple sclerosis (MS) notice a worsening of symptoms or progression just as menopause begins. While getting older is linked with disease progression in both men and women, hormones ...